DRUGS FOR NEGLECTED DISEASES INITIATIVE

A groundbreaking clinical trial for visceral leishmaniasis is underway in Liverpool, testing an oral drug (DNDi-6899) that could replace current painful injection treatments requiring hospitalization.

A new sustained-release formulation of flucytosine for cryptococcal meningitis has entered Phase II trials in Malawi and Tanzania, simplifying dosing from four times to twice daily and improving administration options.